Commodore Capital’s PMV Pharmaceuticals PMVP Stock Holding History

Commodore Capital’s Portfolio PMVP Stock Details PMVP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-125,000	Closed	-$2.6M	–	28
2022 Q1	$2.6M	Hold	125,000	–	–	0.58%	25
2021 Q4	$2.89M	Hold	125,000	–	–	0.67%	24
2021 Q3	$3.73M	Hold	125,000	–	–	0.98%	25
2021 Q2	$4.27M	Hold	125,000	–	–	1.49%	23
2021 Q1	$4.11M	Hold	125,000	–	–	1.64%	25
2020 Q4	$7.69M	Buy	+125,000	New	+$4.9M	4.18%	10

Other funds holding PMVP

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Euclidean Capital New York $392M AUM 31.85% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Commodore Capital's PMVP Position: Q2 2022 in Review

Commodore Capital sold out of PMV Pharmaceuticals (PMVP) in Q2 2022, closing a stake of 125,000 shares — an estimated $2.6M sold.

Commodore Capital first reported a position in PMVP in Q4 2020 and held it in 6 quarters. The position peaked at $7.69M in Q4 2020. 105 funds tracked by Wall St. Rank hold PMVP as of Q2 2022.

Commodore Capital reported no remaining PMV Pharmaceuticals position as of Q2 2022 after selling out during the quarter.
Commodore Capital sold 125,000 PMV Pharmaceuticals shares in Q2 2022, an estimated $2.6M.
Commodore Capital first reported a position in PMV Pharmaceuticals in Q4 2020 and held it in 6 quarters.
Commodore Capital's PMV Pharmaceuticals position peaked at $7.69M in Q4 2020.
105 funds tracked by Wall St. Rank held PMV Pharmaceuticals as of Q2 2022.

Based on Commodore Capital's 13F filing for Q2 2022, filed 15 Aug 2022.